Zelapar;治療藥物分析及市場預測 是由出版商GlobalData在2011年07月所出版的。
這份英文市場調查報告書包含Pages: 31 價格從美金2000起跳。
本報告提供帕金森氏症治療藥物的 Zelapar 平台分析及市場預測，以市場特徵為首，評估分析競爭，開發平台等，加上未來市場競爭，企業簡介等資料，為您概述為以下內容。
1 目錄 1 目錄 2 簡介
- 2.1 帕金森氏症
- 2.2 症狀; 帕金森氏症
- 2.3 診斷; 帕金森氏症
- 2.4 帕金森氏症 治療策略
- 2.5 帕金森氏症 市場
- 2.6 免疫學
- 2.7 帕金森氏症, 年齡及性別
- 2.8 病因論
- 2.9 GlobalData 報告指南
3 帕金森氏症: 市場特性
- 3.1 帕金森氏症 市場
- 3.2 帕金森氏症 市場 預測及年複合成長率
- 3.3 影響因素; 帕金森氏症 市場
- 3.3.1 High 患病率: 帕金森氏症是第二大常見的神經退化性疾病
- 3.3.2 老年人口的增加
- 3.3.3 專利期間的結束; 潛力治療藥物
4 分期; 帕金森氏症及治療方法比較
- 4.1 Hoehn-Yahr 分期法
- 4.2 修正 Hoehn-Yahr 分期法
- 4.3 UPDRS;帕金森氏症統一分期法
5 分期分類; 帕金森氏症
- 5.1 分佈; 帕金森氏症 患者, 各年齡層
- 5.2 各階段患者分佈
6 Zelapar
- 6.1 簡介
- 6.2 作用機制
- 6.3 臨床研究
- 6.4 認證經歷; Zelapar
- 6.5 銷售額的影響因素; Zelapar
- 6.5.1 有效性低
- 6.5.2 在日本未獲認證
- 6.5.3 從傳統的 Selegiline 改用 Zelapar的患者增加
- 6.6 醫藥品評估
- 6.6.1 藥物的風險·好處評估
- 6.6.2 競爭激烈度
- 6.7 銷售額預期
- 6.7.1 目標患者群; 帕金森氏症
- 6.7.2 投藥
- 6.7.3 市場滲透率
- 6.7.4 治療的年度成本;
- 6.7.5 銷售額預期; Zelapar
7 帕金森氏症 市場: 附錄
- 7.1 市場定義
- 7.2 簡稱一覽
- 7.3 調查方法
- 7.3.1 調查範圍
- 7.3.2 二級研究
- 7.3.3 預測
- 7.3.4 可服用藥物的患者數
- 7.3.5 治療藥物的純市場滲透率
- 7.3.6 年度淨投藥數量
- 7.3.7 治療的年度成本;
- 7.3.8 主要研究
- 7.3.9 專家委員會
- 7.4 治療藥物的銷售額預期模式
- 7.5 諮詢方式
- 7.6 免責聲明
- 7.7 資訊來源
1.1 表格一覽
- 表格 1: 臨床運動及非運動症狀; 帕金森氏症
- 表格 2: 帕金森氏症的 Hoehn - Yahr 重症期
- 表格 3: 帕金森氏症的 Hoehn - Yahr 重症期
- 表格 4: UPDRS 之1，第4項
- 表格 5: UPDRS 之2，第13項
- 表格 6: UPDRS 之3，第14項
- 表格 7: UPDRS 之3，第14項
- 表格 8: 分佈; 依Hoehn and yahr分期法分期的帕金森氏症患者
- 表格 9: 平均 OFF時間的變化
- 表格 10: 平均 OFF時間的變化
- 表格 11: 接受藥物治療的患者的不利事件報告;Zelapar
- 表格 12: 認證經歷; Zelapar
- 表格 13: OFF時間的減少, 各上市藥
- 表格 14: OFF時間的減少, 各平台藥
- 表格 15: Zelapar vs. 傳統的 Selegiline
- 表格 16: 藥物的風險·好處評估
- 表格 17: 減少OFF時間的有效性
- 表格 18: 主要 不利事件; Zelapar
- 表格 19: 有效性比較; Zelapar
- 表格 20: 有效性比較; Zelapar
- 表格 21: : 年度成本; Zelapar 帕金森氏症
- 表格 22: Zelapar, 帕金森氏症, 全球市場, 銷售額預期 ($m)
- 表格 23: Zelapar, 帕金森氏症, 美國, 銷售額預期 ($m)
- 表格 24: Zelapar, 帕金森氏症, 英國, 銷售額預期 ($m)
1.2 圖表一覽
- 圖 1: 最新的藥物療法; 帕金森氏症及潛在的作用部位 - CNS(中樞神經系統)
- 圖 2: 各年齡患病率; 帕金森氏症 - EU5個國家的老年人
- 圖 3: 帕金森氏症, 全球市場, 市場規模預測 ($bn)
- 圖 4: 60歲以上人口的比例, 全球, 1950-2050
- 圖 5: UPDRS的分數分佈
- 圖 6: 分佈; 依Hoehn and yahr分期法分期的帕金森氏症患者
- 圖 7: Drug model diagram; Zelapar (支援性治療 - 美國)
- 圖 8: Drug model diagram; Zelapar ( 補助及單劑療法 - 英國)
- 圖 9: Zelapar , 帕金森氏症, 全球市場, 銷售額預期 ($m)
- 圖 10: Zelapar, 帕金森氏症, 美國, 銷售額預期 ($m)
- 圖 11: Zelapar, 帕金森氏症, 英國, 銷售額預期 ($m)
- 圖 12: Drug model diagram
- 圖 13: 可服用藥物的患者數
Abstract
Summary
GlobalData's pharmaceuticals report, "Zelapar - Analysis and Estimates from 2002 to 2020" provides Zelapar sales estimates for US, and UK. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2002-2020). The report also includes information on Parkinson's Disease market. This report is built using data and information sourced from GlobalData's proprietary databases, primary and secondary research using Company's corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts.
Scope
- Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
- Analysis and review of Zelapar including historical sales data
- Qualitative and quantitative assessment of market space
- Analysis of the trends, drivers and restraints shaping and defining the markets
- In-depth analysis of Zelapar including efficacy, safety, pricing, competition and other details which influence its sales potential
- Detailed sales forecast for 2002-2020 for Zelapar in the US & UK
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of competition by understanding the changing competitive landscape
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of the drug's performance
- Examine the historical sales performance of a drug in seven major markets
- Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of contents
1. Table of contents
- 1.1 List of Tables
- 1.2 List of Figures
2. Introduction
- 2.1 Parkinson's Disease
- 2.2 Symptoms of Parkinson's Disease
- 2.3 Diagnosis of Parkinson's Disease
- 2.4 Parkinson's Disease Treatment Strategies
- 2.5 Parkinson's Disease Market
- 2.6 Epidemiology
- 2.7 Parkinson's Disease by Age and Gender
- 2.8 Etiology
- 2.9 GlobalData Report Guidance
3. Parkinson's Disease: Market Characterization
- 3.1 Parkinson's Disease Market
- 3.2 Parkinson's Disease Market Forecasts and CAGR
- 3.3 Factors Affecting Parkinson's Disease Market
- 3.3.1 High Prevalence: Parkinson's Disease is the Second Most Frequent Neurodegenerative Disorder
- 3.3.2 Increase in Old Age Population
- 3.3.3 Patent Expiry of Prominent Drugs
4. Stages of Parkinson's Disease and Comparison of Treatments
- 4.1 The Hoehn and Yahr Scale
- 4.2 Modified Hoehn and Yahr Scale
- 4.3 The UPDRS
5. Staging of Parkinson's Disease
- 5.1 Distribution of Parkinson's Disease Patients by Age Groups
- 5.2 Distribution of Patients by Stages
6. Zelapar
- 6.1 Introduction
- 6.2 Mechanism of Action
- 6.3 Clinical Studies
- 6.4 Approval History of Zelapar
- 6.5 Factors Affecting Sales of Zelapar
- 6.5.1 Low Efficacy
- 6.5.2 Not approved in Japan
- 6.5.3 Patients Switching from Conventional Selegiline to Zelapar
- 6.6 Drug Evaluation
- 6.6.1 Drug Risk Benefit Score
- 6.6.2 Intensity of Competition
- 6.7 Sales Estimates
- 6.7.1 Target Patient Pool for Parkinson 's disease
- 6.7.2 Dosing
- 6.7.3 Market Penetration
- 6.7.4 Annual Cost of Therapy
- 6.7.5 Sales Estimates of Zelapar
7. Parkinson Disease Market: Appendix
- 7.1 Market Definitions
- 7.2 List of Abberiviations
- 7.3 Research Methodology
- 7.3.1 Coverage
- 7.3.2 Secondary Research
- 7.3.3 Forecasting
- 7.3.4 Number of Patients Approved to take the Drug
- 7.3.5 Net Penetration of Drug
- 7.3.6 Net Annual Dosing
- 7.3.7 Annual Cost of Therapy
- 7.3.8 Primary Research
- 7.3.9 Expert Panels
- 7.4 Drug Sales Estimates Model
- 7.5 Contact Us
- 7.6 Disclaimer
- 7.7 Sources
List of Tables
- Table 1: Clinical Motor and Nonmotor Features of Parkinson's Disease
- Table 2: Hoehn and Yahr Stages of Parkinson's Disease
- Table 3: Hoehn and Yahr Stages of Parkinson's Disease
- Table 4: Four Items, Part 1 of UPDRS
- Table 5: Thirteen Items, Part 2 of UPDRS
- Table 6: Fourteen Items, Part 3 of UPDRS
- Table 7: Fourteen Items, Part 3 of UPDRS
- Table 8: Distribution of Parkinson's Patients According to Hoehn and Yahr Classification
- Table 9: Change in Mean total daily "OFF" time
- Table 10: Change in Mean Total Daily "OFF" Time
- Table 11: Adverse Events Reported by Patients Treated with Zelapar
- Table 12: Approval History of Zelapar
- Table 13: Reduction in OFF Time Reported by Marketed Drugs
- Table 14: Reduction in OFF Time Reported by Pipeline Drugs
- Table 15: Zelapar vs. Conventional Selegiline
- Table 16: Drug Risk Benefit Score
- Table 17: Efficacy in Terms of Reduction in OFF Time
- Table 18: Major Adverse Events Reported by Zelapar
- Table 19: Efficacy comparison of Zelapar
- Table 20: Efficacy comparison of Zelapar
- Table 21: : Annual Cost of Zelapar for Parkinson's Disease, 2010
- Table 22: Zelapar, Parkinson's Disease, Global, Sales Estimates ($m), 2002-2020
- Table 23: Zelapar, Parkinson's Disease, The US, Sales Estimates ($m), 2006-2020
- Table 24: Zelapar, Parkinson's Disease, UK, Sales Estimates ($m), 2002-2020
List of Figures
- Figure 1: Current Pharmacologic Therapies for Parkinson's disease and Their Potential Sites of Action in the CNS
- Figure 2: The Age-Specific Prevalence Rates of Parkinson's Disease in the Elderly Among Five European Countries, 2003
- Figure 3: Parkinson's Disease, Global, Market Size Estimates ($bn), 2010-2020
- Figure 4: Proportion of Population 60 Years or Older, World, 1950-2050
- Figure 5: Points Distribution of UPDRS
- Figure 6: Distribution of Parkinson's Disease Patients by Hoehn & Yahr Classification
- Figure 7: Drug Model Diagram of Zelapar (Adjunct therapy in the US)
- Figure 8: Drug Model Diagram of Zelapar ( Adjunct and Monotherapy in UK)
- Figure 9: Zelapar , Parkinson's Disease, Global, Sales Estimates ($m), 2002-2020
- Figure 10: Zelapar, Parkinson's Disease, The US, Sales Estimates ($m), 2006-2020
- Figure 11: Zelapar, Parkinson's Disease, The UK, Sales Estimates ($m), 2002-2020
- Figure 12: Drug Model Diagram
- Figure 13: Patients Approved for the Drug
|
